Skip to content
Nursing Writing CenterReliable · Trusted · Professional
MSN sampleAdvanced pathophysiology Walden UniversityMSN — Advanced Pathophysiology

Pathophysiology Concept Map: Type 2 Diabetes and Kidney Disease

Paper type
Concept map
Length
5 pages
Citation style
APA 7
Sources
6

Abstract

An advanced pathophysiology concept map tracing how insulin resistance and chronic hyperglycemia lead to diabetic kidney disease in a 58-year-old patient. It links cellular mechanisms to labs such as eGFR and the urine albumin-to-creatinine ratio, and to the evidence for ACE inhibitors and SGLT2 inhibitors in slowing progression.

Outline

  1. 1Case summary
  2. 2Insulin resistance and beta-cell dysfunction
  3. 3Hyperglycemia and glomerular injury
  4. 4Labs and staging: eGFR and albuminuria
  5. 5Pharmacologic targets on the map
  6. 6Implications for advanced practice

Excerpt

The case at the center of this map is Ms. T., a 58-year-old with an 11-year history of type 2 diabetes and hypertension. Her most recent labs show an A1C of 8.4%, an eGFR of 52 mL/min/1.73 m² and a urine albumin-to-creatinine ratio (UACR) of 210 mg/g. She takes metformin and amlodipine. The map is built in three layers — cellular mechanisms, organ-level changes and clinical findings — so that each lab value can be traced back to the process that produced it.

At the cellular layer, insulin resistance in muscle, liver and adipose tissue forces the beta cells to secrete more insulin until they begin to fail, and blood glucose rises. Chronic hyperglycemia then injures the kidney through several linked pathways, including advanced glycation end products, activation of the renin-angiotensin-aldosterone system and glomerular hyperfiltration (Alicic et al., 2017; Rogers, 2023). Higher pressure inside the glomerulus damages the filtration barrier, which is why albumin often appears in the urine before the eGFR falls.

The clinical layer stages her disease using both measures. An eGFR of 52 places her in category G3a and a UACR of 210 mg/g in category A2, a combination that KDIGO classifies as high risk for progression (Kidney Disease: Improving Global Outcomes [KDIGO] Diabetes Work Group, 2022). Arrows from the mechanism layer point to the treatments that act on each step. An ACE inhibitor or ARB lowers intraglomerular pressure and albuminuria, and an SGLT2 inhibitor reduces hyperfiltration and is recommended for adults with type 2 diabetes and chronic kidney disease whose eGFR is 20 or higher (American Diabetes Association Professional Practice Committee, 2025). Because her eGFR is above 45, metformin can continue at the current dose, with kidney function and potassium rechecked after any change to her ACE inhibitor or ARB.

The full paper continues for 5 pages

Need a custom paper on your own topic and rubric? A MSN-level writer can start today.

Order a similar paper

References (selected)

  • Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017). Diabetic kidney disease: Challenges, progress, and possibilities. Clinical Journal of the American Society of Nephrology, 12(12), 2032–2045.
  • American Diabetes Association Professional Practice Committee. (2025). Standards of care in diabetes—2025. Diabetes Care, 48(Suppl. 1).
  • Kidney Disease: Improving Global Outcomes Diabetes Work Group. (2022). KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International, 102(5S), S1–S127.
  • Rogers, J. L. (Ed.). (2023). McCance & Huether’s pathophysiology: The biologic basis for disease in adults and children (9th ed.). Elsevier.

This sample is published to show our writing quality. Do not submit it as your own work — it is publicly available and will be detected by plagiarism checkers. The university and course show the kind of assignment it models; we are not affiliated with Walden University.

More Walden University samples

Need help with a nursing paper today?

Get matched with a BSN, MSN or DNP-qualified writer in minutes. First order 15% off.